Candida krusei that showed high susceptibility to voriconazole. The situation in Turin, Italy, is quite similar to that of the rest of Italy, reflecting the worldwide trend.
Scientific Inc., Santa Barbara, CA) (8). The BIOMIC system provides a cost-effective means to electronically read and interpret test plates and to collect and transfer data; moreover, the BIOMIC system provides improved intra-and interlaboratory reading consistency (5, 7, 13, 19) .
A total of 1,024 yeast isolates were collected from various specimens (blood, normally sterile body fluids, deep tissue, genital tract, gastrointestinal tract, and respiratory tract) from three participating hospitals in Turin and Biella, Italy, between January 2002 and December 2006. All strains were identified by ID32C panels (bioMérieux, Rome, Italy).
Fluconazole and voriconazole susceptibility testing was performed in accordance with CLSI document M44-A for yeasts (8) . For quality control, C. albicans ATCC 90029 was used in accordance with CLSI document M44-A (8) . Fluconazole (25 g) and voriconazole (1 g) disks were manufactured and supplied by Becton Dickinson, Sparks, MD. Zone diameter endpoints were automatically read at 80% growth inhibition and interpreted using the BIOMIC image analysis plate reader system (Giles Scientific, Inc.) (5, 9, 13) . The interpretive criteria for fluconazole and voriconazole disk diffusion tests were performed in accordance with CLSI (2, 8) . The MICs were determined by the BIOMIC system that uses species-specific linear regression analysis to correlate all zone diameters from the disk diffusion test with corresponding MICs from the reference dilution method (12) . The corresponding MIC breakpoints were those of CLSI (2, 8) . An excellent correlation between the MIC and the zone diameter has been observed in previous studies (5, 12) . Hence, fluconazole and voriconazole MIC 50 s and MIC 90 s were calculated and reported.
The species distribution and the in vitro susceptibilities of 1,024 Candida isolates to fluconazole and voriconazole are summarized in Table 1 . In agreement with the international literature (1, 5, 13) , we found that in Turin, Italy, C. albicans was the most common yeast species but the C. albicans frequency (55.6%) was slightly lower than that reported by other authors both in Italy (3, 19) and worldwide (5, 7, 12, 13) . Four hundred twenty-seven strains (39.7%) were non-C. albicans spp. Among these, C. glabrata (18.7%) was the first most common yeast pathogen, followed by C. tropicalis (5.5%) and C. parapsilosis (4.7%). Our findings confirm the worldwide pattern (12, 19) . The frequency of C. krusei (2.6%) in our study was also similar to the 1.8 to 2% reported by other authors (1, 5, 6, 12, 19) , while the percentage of C. kefyr in our study was higher (2.2%) than that reported in previous studies in Italy and worldwide (0.6%) (5, 13, 19) . C. kefyr may be considered an emerging pathogen (15) ; however, few data are available about this pathogen. The frequency of C. norvegensis and C. valida did not vary markedly over the 5-year study period (data not shown) (5, 13, 19) . Unusual Candida species (C. holmii, C. humicola, C. intermedia, C. lambica, C. lusitaniae, C. membranifaciens, C. rugosa, and C. utilis) constituted only a small percentage (1.4%) ( Table 1) .
The results of our antifungal susceptibility testing in Turin, Italy, are generally consistent with the findings from other Italian studies (3, 19) and with other sites globally in the ARTEMIS Global Antifungal Surveillance Group (5, 12, 13) . Despite the widespread use of fluconazole for more than a decade, we found no evidence that C. albicans (98% susceptible) has developed increased resistance to fluconazole. Fluconazole was most active against C. parapsilosis (96% susceptible), C. tropicalis (92% susceptible), and C. kefyr (96% susceptible). Decreased susceptibility to fluconazole was seen for C. glabrata (82% susceptible). C. krusei remains primarily a pathogen that is fluconazole resistant. The observation that 32% of C. krusei strains were susceptible and susceptible dose dependent to fluconazole was unexpected, but other investigators have reported similar findings (3, 7) . As C. krusei isolates are assumed to be intrinsically resistant to fluconazole (6), their inhibition zone diameters and MICs should not be interpreted using breakpoints established by CLSI (2, 8) . According to Sugita et al. (17) , fluconazole resistance was also observed in C. norvegensis, C. valida, and C. inconspicua; these three opportunistic fungal pathogens are rarely isolated from patients but are considered to be emerging pathogens in humans. The uncommon Candida species were all susceptible to the drug (Table 1) .
Compared to fluconazole, voriconazole showed an excellent in vitro potency and broad-spectrum activity against all tested species, including many yeasts that were found to be resistant to fluconazole, such as C. krusei, which showed high susceptibility to voriconazole (92%). Although voriconazole was highly active against C. glabrata, resistance to voriconazole was detected (Table 1) , as confirmed by the worldwide data reported by Pfaller et al. (12, 13) . This decreased susceptibility of C. glabrata to multiple azole drugs may be ascribed to the broad current usage of fluconazole and/or itraconazole for the treatment of infections due to Candida spp. and other opportunistic yeasts and yeastlike fungi (10) . We found that voriconazole was highly active against most rare Candida species, such as C. dubliniensis, C. famata, C. guilliermondii, C. holmii, C. humicola, C. intermedia, C. lusitaniae, C. membranifaciens, C. pulcherrima, and C. utilis. We found that a high percentage of C. valida isolates were resistant to fluconazole but susceptible to voriconazole (Table 1) ; this species has been emerging in recent years (5, 13) .
MIC ranges, MIC 50 s, and MIC 90 s for fluconazole and voriconazole are listed in Table 2 . Voriconazole inhibited 90% of the isolates at a concentration six to eight times lower than that determined for fluconazole. C. krusei and C. glabrata fluconazole MICs were markedly higher than those for voriconazole (256 versus 2 g/ml and 64 versus 4 g/ml, respectively).
There was very little variation in the rates of resistance of Candida isolates to either fluconazole and voriconazole over the study period (2002 to 2006) (data not shown). Only C. kefyr In conclusion, our data revealed that the resistance to fluconazole among pathogenic yeasts is still a restricted phenomenon in Turin, Italy. We confirm that voriconazole is a promising antifungal triazole that appears to be more active against infections caused by yeasts intrinsically resistant to fluconazole and by many less-common species. The susceptibility patterns and trends observed in Turin are similar to those observed elsewhere in Italy, reflecting the worldwide patterns (7, 9, 12) . 
